Short answer
Nuvectis Pharma, Inc. (NVCT) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$7M
- −10.8% YoY · −16.0% QoQ
- EPS (diluted)
- −$0.30
- −3.4% YoY · −15.4% QoQ
Source: XBRL data from the Nuvectis Pharma, Inc. (NVCT) Q2 2026 10-Q on SEC EDGAR. USD.
Nuvectis Pharma, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no revenue generated since inception
- Operating loss $7.197M vs $6.595M YoY; operating margin not meaningful with zero revenue
- R&D expenses $4.684M, up 30% YoY; NXP900 clinical and manufacturing costs up $0.8M
- Cash $22.2M at June 30; operating cash use $11.042M vs $7.541M YoY
- July offering net proceeds approximately $106.3M; funding expected through at least next 12 months
Risk Factors
- Newly added tariff risk, triggered by U.S. trade-policy changes, potentially increasing raw-material, reagent, and laboratory-equipment costs
- Most material financial risk: accumulated deficit of $112.8 million through June 30, 2026, with continued losses expected
- Regulatory disruption risk from FDA or SEC funding shortfalls and government shutdowns delaying approvals or public-market access
- Clinical-development risk: NXP800 development ceased in platinum-resistant ARID1a-mutated ovarian carcinoma after preliminary Phase 1b analysis
- Operational supply-chain risk from tariffs or trade restrictions disrupting availability of clinical materials and logistics
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvectis Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.